Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for Madrigal Pharmaceuticals (MDGL) over the last 4 years, with Dec 2024 value amounting to $162,000.

  • Madrigal Pharmaceuticals' Gains from Investment Securities was N/A to $162,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $3.4 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is 18.30% down from last year.
  • As of Q4 2024, Madrigal Pharmaceuticals' Gains from Investment Securities stood at $162,000, which was down 86.50% from $1.2 million recorded in Q3 2024.
  • In the past 5 years, Madrigal Pharmaceuticals' Gains from Investment Securities registered a high of $1.6 million during Q3 2023, and its lowest value of $162,000 during Q4 2024.
  • Its 2-year average for Gains from Investment Securities is $996,667, with a median of $1.2 million in 2024.
  • Data for Madrigal Pharmaceuticals' Gains from Investment Securities shows a maximum YoY decreased of 26.29% (in 2024) over the last 5 years.
  • Over the past 3 years, Madrigal Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $451,000 in 2020, then reached $1.6 million in 2023, then dropped by 26.29% to $162,000 in 2024.
  • Its last three reported values are $162,000 in Q4 2024, $1.2 million for Q3 2024, and $1.6 million during Q3 2023.